tirzepatide through lilly Eli sues companies selling alternative versions of its weight loss drug FDA approves Eli Lilly's tirzepatide

To enhance the appetite-suppressing effects of tirzepatide, focus on maintaining a healthy diet and regular exercise

According to Lillys TRIUMPH-4 release, the most common adverse events with retatrutide were gastrointestinal: nausea diarrhea constipation vomiting decreased appetite Lilly also reported dysesthesia , an altered skin-sensation signal, in: 8.8% of participants on 9 mg 20.9% of participants on 12 mg compared with 0.7% on placebo Those events were generally mild and rarely led to discontinuation, but they are still notable because dysesthesia did not become a headline feature of the earlier semaglutide narrative

Fujita, H

Speak to your doctor, as you may need to restart at a lower dose

Theyre telling me they used to drink a glass of wine at night and now they dont feel like it anymore, he says